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Abstract
Background: Since 2001 the South African guidelines to improve child health and prevent vertical HIV
transmission recommended frequent infant follow-up with HIV testing at 18 months postpartum. We sought
to understand non-attendance at scheduled follow-up study visits up to 18 months, and for the 18-month
infant HIV test amongst a nationally representative sample of HIV exposed uninfected (HEU) infants from a
high HIV-prevalence African setting.
Methods: Secondary analysis of data drawn from a nationally representative observational cohort study (conducted
during October 2012 to September 2014) of HEU infants and their primary caregivers was undertaken. Participants
were eligible (N = 2650) if they were 4–8 weeks old and HEU at enrolment. All enrolled infants were followed up every
3 months up to 18months. Each follow-up visit was scheduled to coincide with each child’s routine health visit, where
possible. The denominator at each time point comprised HEU infants who were alive and HIV-free at the previous visit.
We assessed baseline maternal and early HIV care characteristics associated with the frequency of ‘Missed
visits’ (MV-frequency), using a negative binomial regression model adjusting for the follow-up time in the
study, and associated with missed visits at 18 months (18-month MV) using a logistic regression model.
Results: The proportion of eligible infants with MV was lowest at 3 months (32.7%) and 18 months (31.0%)
and highest at 12 months (37.6%). HIV-positive mothers not on triple antiretroviral therapy (ART) by 6-weeks
postpartum had a significantly increased occurrence rate of ‘MV-frequency’ (adjusted incidence rate ratio, 1.2
(95% confidence interval (CI), 1.1–1.4), p < 0.0001). Compared to those mothers with ART, these mothers also
increased the risk of ‘18-month-MV’ (adjusted odds ratio, 1.3 (CI, 1.1–1.6), p = 0.006). Unknown infant
nevirapine-intake status increased the rate of ‘MV-frequency’ (p = 0.02). Mothers > 24 years had a significantly
reduced rate of ‘MV-frequency’ (p ≤ 0.01) and risk of ‘18-month-MV’ (p < 0.01) compared to younger women.
Shorter travel time to health facility lowered the occurrence of ‘MV-frequency’ (p ≤ 0.004).
Conclusion: Late initiation of maternal ART and infant prophylaxis under the Option- A policy and extended
travel time to clinics (measured at 6 weeks postpartum), contributed to higher postnatal MV rates. Mothers
older than 24 years had lower MV rates. Targeted interventions may be needed during the current PMTCT
Option B+ (lifelong ART to pregnant and lactating women at HIV diagnosis) to circumvent these risk factors
and reduce missed visits during HIV-care.
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Background
Optimal management of HIV in infants and children
has been a challenge in low-middle income countries,
resulting in missed opportunities for initiating timely
treatment and averting adverse outcomes [1]. The
reasons for sub-optimal care, despite well-structured
guidelines for monitoring and follow-up, are complex
and intertwined between the user and provider-related
factors. Despite having made good progress in adult
HIV treatment in South Africa, the country is still
faced with a high loss to follow-up of HIV-exposed
infants mainly during the high-risk breastfeeding
period, with concomitant low coverage of infant HIV
treatment [2, 3]. Data from a 2010 national survey in
South Africa illustrates that 38% of early infant HIV
testing opportunities are missed as a result of poor
documentation of infant HIV exposure status or no
maternal request for a test [4]. Other factors that
contribute to unsatisfactory HIV care in children in-
clude poor parental uptake of HIV services, fear of
stigmatization, limited knowledge about the modes of
vertical HIV transmission (MTCT), young maternal
age and low socioeconomic status [4–6].
Notwithstanding improved prevention of MTCT
(PMTCT) policies from 2002 until 2015, the infant rapid
HIV test at 18 months continues to mark the end point
of the PMTCT programme, serving as a measure of
PMTCT effectiveness [7]. Additionally, since 2005 the
Integrated Management of Childhood Illness (IMCI)
strategy, recommends that all infants, regardless of HIV
exposure status, receive monthly routine growth moni-
toring and care (well-baby visits) during the first year of
life, and every 3 months thereafter. There is little data on
factors associated with non-attendance at scheduled
child health care visits in the context of HIV.
We aimed to measure non-attendance at intermit-
tently scheduled study follow-up visits, and at the final
18-month exit visit, amongst HIV-exposed uninfected
(HEU) infants enrolled in a nationally-representative
survey to measure postnatal PMTCT effectiveness. We
also sought to identify factors associated with non-at-
tendance at these visits to shed light on possible inter-
ventions to improve postnatal follow-up.
Methods
Study data and aims
Secondary analysis of data drawn from a nationally rep-
resentative observational cohort study of HEU infants
and their primary caregivers was conducted. The main
study, conducted between October 2012 and September
2014, aimed to measure postnatal mother-to-child trans-
mission of HIV (MTCT) between 6 weeks and 18
months postpartum and these primary results are being
presented in a separate manuscript. The cohort was
recruited from 6 weeks postpartum cross-sectional sur-
vey conducted in 2012 whose methods have been previ-
ously published [8]; briefly, the study was conducted at
public primary health care clinics and community health
centres nationwide offering immunisation services. A na-
tionally-representative sample of facilities was selected
through a multistage probability proportional to size
sampling approach. HIV Enzyme-linked immunosorbent
assay (EIA) was used to confirm infant HIV exposure at
6 weeks of age. Infants who were HIV-exposed but not
HIV PCR positive (i.e., HEU infants) at 6 weeks old were
eligible for postnatal follow-up. Ethics approval for the
study was granted by the South African Medical Re-
search Council Ethics Committee, and approval was also
obtained from the Centers for Disease Control and Pre-
vention. All caregivers signed informed consent. The 6
week and 18 month HIV tests in this study were routine
tests. A final sample of 2650 eligible caregiver-infant
pairs who provided signed informed consent to take part
in the cohort study was used in this secondary analysis.
The cohort was followed up from October 2012 until
September 2014. Participants were given study incon-
venience allowances at each visit of USD$2.50 in
October 2012, increased to USD$6.00 in January 2014.
PMTCT Option A policy (maternal AZT plus infant
ARV prophylaxis to prevent MTCT and infant prophy-
laxis until 1 week after cessation of breastfeeding) was in
use in South Africa during the start of the study to
March 2013. Subsequently, PMTCT Option B (maternal
triple ARV prophylaxis to prevent MTCT and infant
prophylaxis for the first 4–6 weeks regardless of feeding
status) was adopted in April 2013 and was in use during
the remainder of the study period [9].
The recruited HEU infants and their caregivers were
followed up at 3, 6, 9, 12, 15 and 18months post-par-
tum. Data collectors attempted to coincide these study
follow-up visits with routine follow-up visits during the
same time interval and drew blood for infant HIV test-
ing at each of the visits. Socio-demographic background
information were collected at 6 weeks postpartum (base-
line). Since the primary outcome for the cohort study
was HIV incidence and death in HIV-exposed infants,
the length of follow-up for each infant was determined
by one of the following three scenarios: (i) until study
end-point at 18 months postpartum if they remained
HIV negative; (ii) up-to-the time point of infant serocon-
version where after they presented for one exit interview
to assess access to care or lastly, (iii) up-to-the time of
death if they died before the study end-point or before
HIV seroconversion.
This secondary analysis focusses on non-attendance of
the six scheduled postnatal care study visits (at 3, 6, 9,
12, 15 and 18 months postpartum) and non-attendance
of the 18-month postpartum visit.
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Describing patterns of ‘missed visits’
We studied non-attendance at scheduled visits, operatio-
nalised as ‘missed visit’, (abbreviated here as MV), for an
infant who was eligible for that visit. Infants eligible for
a visit were those enrolled at baseline who were alive
and free of HIV at the previous visit. Repeated MV was
observed for some participants; therefore, we also
present simple proportions with 95% confidence inter-
vals (CI) of MV at each follow-up study time point, i.e.,
per time-point MV.
Two scenarios of MV were of primary interest: The first,
(i) ‘MV frequency’ defined as the number of MV across a
participant’s exposure time over the study period. Expos-
ure time is simply the number of months linked to sched-
uled eligible study visit points up to the end of the study
(18months postpartum) or time of death or HIV-infec-
tion. In this case, MV was a count variable, counting the
number of missed eligible visits from 0 (attended all of
them) through to 6 (was eligible for all study visits and
never attended any of them). Exposure time ranged from
1 (if death or HIV-infection occurred at the 3-month
point) to 6 (if either HIV-infection or death occurred after
18months or never occurred during the study period. The
second, (ii) 18-month MV, was a binary variable of failure
to attend or not among those still eligible to attend this
visit. The 18-month MV was of special interest because
this visit was scheduled to coincide with the routine 18-
month postpartum rapid HIV testing of the enrolled
infant and the exit point from the PMTCT programme.
Independent factors tested for association with MV
Purposively selected baseline socio-demographic char-
acteristics, and health-care information was assumed
to have some direct or indirect influence on the up-
take of scheduled visits. The independent variables
were evaluated for potential association with MV in-
cluding relationship between the caregiver and the
infant at the six-week enrolment, mother’s age,
mother’s highest education level, marital status. We
also evaluated whether infant was ever breastfed, dis-
closure of maternal HIV status to family or friends,
ever facing discrimination due to HIV status, know-
ledge of MTCT modes, maternal ART use at 6 weeks
postpartum, whether infant had been given nevirapine
after birth, infant birth weight, infant hospitalization,
means of transport used and time taken to access the
facility, socio-economic status (SES) ranking and
province. SES was extracted from a calculation using
the full cross-sectional sample available at 6 weeks
postpartum. In the full cross-sectional dataset, SES
was calculated using principal component analyses
from household characteristics (which included the
type of housing, sanitation, water and fuel), household
possessions (such as TV, stove, radio), any food
shortage and source of income [10]. A Chi-squared
test was used in the descriptive statistics of these
independent variables at baseline and by ‘per time-
point MV’.
None of the chosen independent variables had more
than 10% missing data. Of those with some missing data,
if excluding missing data changed the 95% CI of ob-
served estimates on known categories of the variable,
then an additional category for ‘unknown’ responses was
added to the variable in the statistical and descriptive
analyses in order to minimise deviation from actual ob-
served estimates and to keep the survey structure and
sampling weights accurate on the rest of the data.
Identifying factors associated with MV
Two sets of analyses were conducted, to assess factors
associated with ‘MV frequency’, and ‘18-month MV’,
separately.
To assess the former, a regression model for a
count outcome variable allowing varying exposure
time periods was most suitable for the data. However,
the assumption of a Poisson regression model for a
count outcome (i.e., data are not overly dispersed),
was not met. Considering that the outcome was ex-
pected to have zeros from participants who missed all
their eligible visits (exposed), a zero-inflated binomial
regression model was used to confirm whether the
data were zero-inflated. The assumption of zero-infla-
tion was rejected (z = 6.44, p < 0.0001). The final
model used for identifying predictors of MV fre-
quency was, therefore, a negative binomial regression,
with survey set functions and exposure times specified
[11, 12]. Bivariate analyses were first run between
each independent factor and the primary outcome
and a Wald test (corrected for survey structure and
including the exposure time variable) performed to
see if the coefficients were significantly non-zero
using a p-value cut-off of < 0.25. Independent factors
with a Wald test p < 0.25 were then included in a
multivariable analysis model. Those factors which had
overall non-significant Wald tests but with p < 0.05
for the coefficients of sub-categories were then in-
cluded in the multivariable model and retained if they
caused a large change (a shift of the 95% CI) on the
coefficients of any variables which were already in the
model.
The final multivariable model included seven of the 15
independent variables; maternal age, caregiver status, the
disclosure of maternal HIV status, infant ever being on
nevirapine, the mother being on ART, common means
of transport and province. Adjusted point estimates are
presented here.
To identify factors associated with ‘18-month MV’, a
logistic regression model, with survey settings specified,
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was used. For ‘18-month MV’, ten factors (maternal age,
education level, whether infant ever breastfed, disclosure
of maternal HIV status, being discriminated against,
knowledge of MTCT modes, mother being on ART at 6
weeks, infant having taken nevirapine by 6 weeks, SES
and province) were eligible for inclusion in the final
multivariable model.
All analyses were performed in STATA SEv13.
Sampling weights were applied to all reported pro-
portions and statistical analyses to adjust for sample
ascertainment in the original cohort and non-con-
sent for postnatal follow-up amongst all those eli-
gible for postnatal enrolment.
Results
Baseline characteristics of the cohort
The majority of caregivers at 6 weeks postpartum (base-
line) were the infants’ mothers (97.6%), with a mean ma-
ternal age of 29 years (interquartile range 24;33 years).
Three age-groups were used for analyses in the enrolled
sample, adolescents and young adults (< 14–25 years old,
23.3%), 25–34 years of age women (58.2%) and older
women (at least 35 years old), Table 1. Most caregivers
had achieved at least 7 years of schooling (81.0%) and
were either single, widowed or divorced (78.0%). Only
27.3% of infants had never been breastfed during the
first 6 weeks of life. Seventy-seven percent of mothers
had disclosed their HIV status to family or friends, but
only 8.6% reported ever feeling discriminated against
due to their HIV status. Eighty-nine percent of care-
givers knew at least one mode of MTCT; 52.3% of
mothers were on ART and 85.6% of infants had received
nevirapine prophylaxis by the first 6 weeks of life. Over-
all 13.9% of enrolled infants had low birth weight and
5.1% had been hospitalised by 6 weeks postpartum. Al-
though 4 % of women used their cars to travel to the
clinic, 77.1% reached the health facility in under 30 min
by either walking or using public transport.
Patterns of MV per time-point
The lowest levels of MV per time point were at 3 and 18
months postpartum (32.7, 95% CI 30.8–34.7, and 31.0,
95% CI 29.0–33.0, respectively), (see Additional file 1 for
baseline characteristics by patterns of MV per time point).
For 6, 9, 12 and 15month visits, MV ranged between 36.0
and 37.6% with no significant differences between the
four-time points. Overall, the weighted percentages of MV
appeared to differ significantly (p < 0.05) by type of care-
giver who brought child at baseline, mother’s age, disclos-
ure of mother’s HIV status to family or friends,
discrimination, maternal ART, infant prophylaxis, means
of travel to facility and province at which a participant
resided.
Table 1 Characteristics of the study population at baseline
(N = 2650)
Characteristic n weighted % (95% CI)
Caregiver
Mother 2607 97.6 (96.7–98.3)
Other 43 2.4 (1.7–3.3)
Mother’s age~
13–24 years 681 23.3 (21.5–25.2)
25–34 years 1480 58.2 (56.0–60.3)
35–50 years 482 18.1 (16.5–19.7)
Education~
Grade 7 and below 525 18.8 (17.3–20.5)
Grade 8 and above 2121 81.0 (79.4–82.5)
Marital status~
Married/cohabit 648 22.0 (20.4–23.7)
Single/widow/divorced 2000 78.0 (76.3–79.6)
Ever Breastfed~
Yes 1880 72.7 (70.9–74.5)
No 702 27.3 (25.5–29.1)
Disclosure of HIV mother’s statusa
Yes 2087 76.5 (74.6–78.3)
No 455 17.4 (15.9–19.1)
Unknown 108 6.1 (5.0–7.4)
Discriminated against regarding HIV statusa
Yes 220 8.6 (7.5–9.9)
No 2322 85.3 (83.6–86.9)
Unknown 108 6.1 (5.0–7.4)
Knows MTCT modesa
Yes 2327 88.6 (87.2–89.8)
No 87 3.3 (2.6–4.2)
Unknown 236 8.2 (7.1–9.3)
Mother on ART by 6 weeksa
Yes 1445 52.3 (50.2–54.4)
No 1083 41.1 (39.1–43.2)
Unknown 122 6.6 (5.5–7.9)
Infant on NVP by 6 weeksa
Yes 2329 85.6 (84.0–87.1)
No 114 4.5 (3.7–5.5)
Unknown 207 9.9 (8.5–11.3)
Infant birth weight~
< 2.5 kg 374 13.9 (12.5–15.4)
2.5 kg + 2208 86.1 (84.6–87.5)
Infant hospitalised~
Yes 123 5.1 (4.2–6.1)
No 2525 94.9 (93.9–95.8)
Travel to facility
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A significantly higher proportion of 3 and 6 month
visits were missed by infants brought by caregivers
who were not their mothers at baseline (at 3
months = 70.2% versus 31.8% and at 6 months = 62.2%
versus 35.8%, p < 0.0001 and p = 0.002 respectively).
Differences in MV per time-point by maternal age
were measured at 6, 12, 15 and 18 months postpar-
tum. The youngest age-group of women, in particular,
tended to have higher percentage of MV compared to
the two older age-groups. MV at all time points ex-
cept 18 months was significantly less in mothers who
disclosed their HIV status at baseline. In the case of
discrimination, significant differences were seen at 3,
6 and 9 months, where the lowest proportions of MV
were among women who reported not being discrimi-
nated against due to their HIV status and the highest
proportions among those with unknown responses.
Lower uptake of infant nevirapine or maternal ART
was related to MV at 3, 6 and 9 months and at all
time points, respectively. Additionally, MV was high-
est among those with missing information about in-
fant nevirapine or maternal ART. A significant
difference in MV by mode of transport to the clinic
was measured at the 15-month point (p = 0.02), and
the highest MV was among women who used their
cars and lowest amongst all those who walked or
used public transport. There was no significant differ-
ence in MV by SES ranking, but MV differed signifi-
cantly by province at all time points.
Factors associated with ‘MV-frequency’
In total, 58.8% (95% CI 56.7–60.8) missed at least
one scheduled follow-up visit (Table 2). The fre-
quencies of missed visits by a number of scheduled
visits, i.e., a breakdown of the MV-frequency, are
shown in Additional file 2. Results from the negative
binomial regression analyses adjusted for exposure
time, mother’s age, type of caregiver interviewed at
6 weeks, maternal ART use at 6 weeks postpartum,
whether infant had been given nevirapine after birth,
disclosure of maternal HIV status, means of trans-
port used and time taken to access the facility and
province, demonstrated that the adjusted incidence
rate ratio (aIRR) for‘MV-frequency’ tended to be sig-
nificantly lower among older women (> 24 years of
age) compared to adolescents and young adults (13–
24 years old) and among those who had quick access
to health facilities (less than 30 min) by either walk-
ing or using public transport compared to those who
owned cars, but higher amongst mothers who were
not on ART by 6 weeks postpartum and caregivers
who did not know about infant intake of nevirapine
(Table 2). To confirm whether young maternal age
could be influencing delayed uptake of ART (i.e. not
by 6 weeks post-partum), we included an interaction
term of the two to the model but this effect was not
significant and thus excluded from the final model.
Differences between provinces were also evident.
Factors associated with ‘MV at 18months’
After adjusting for all other independent factors in the
final multivariable model, no maternal ART use by 6
weeks post-delivery significantly increased ‘MV at 18
months’ (adjusted OR (aOR) 1.3 (1.1–1.6), p = 0.006),
whilst older maternal age significantly protected against
MV at the 18-month visit point (aOR 0.7 (0.5–0.9), p =
0.001 for 25–34 year olds and p = 0.011 for 35 years old
and older mothers) (Table 3). All provinces except for
Northern Cape, had significantly higher odds of MV at
18month visit point compared to the Western Cape
Province. This model was controlled for maternal
education; infant ever breastfed, the disclosure of mater-
nal HIV status, having been discriminated against,
knowledge of MTCT modes, the infant having taken ne-
virapine and SES.
Table 1 Characteristics of the study population at baseline
(N = 2650) (Continued)
Characteristic n weighted % (95% CI)
Own car 99 3.6 (2.9–4.4)
Walked < 30 min 1182 41.4 (39.4–43.4)
Walked > 30 min 283 10.4 (9.2–11.8)
Public transport < 30min 872 35.7 (33.7–37.8)
Public transport > 30min 214 8.9 (7.7–10.2)
SESb
Highest 557 21.1 (19.4–22.8)
High 459 16.9 (15.4–18.5)
Middle 540 19.9 (18.4–21.6)
Low 543 20.5 (18.9–22.3)
Lowest 551 21.5 (19.9–23.3)
Province
WC 246 6.5 (5.7–7.4)
NW 221 6.9 (6.0–7.8)
NC 84 1.5 (1.2–1.8)
MP 315 9.6 (8.6–10.7)
LP 266 9.3 (8.2–10.5)
KZN 442 26.8 (24.8–28.9)
GP 524 24.3 (22.5–26.2)
FS 275 5.2 (4.6–5.9)
EC 277 10.0 (8.9–11.2)
aa category for missing data was included. ~less than 3% missing data
bSES was calculated using all the data enrolled in the original cross-sectional
survey at 6 weeks. South African provinces- WC-Western Cape, NW-North West,
NC-Northen Cape, MP-Mpumalanga, LP-Limpopo, KZN-KwaZulu Natal, GP-
Gauteng, FS-Free State, EC-Eastern Cape
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Discussion
Using data from a nationally representative observa-
tional cohort study which aimed to synchronise study
follow-up visits for HEU infants with their recom-
mended or planned routine postnatal follow-up visits
where possible, we demonstrate that, ~ 59% of HEU
infants did not attend one or more scheduled visits
between 3 and 18 months postpartum. The lowest
MV occurred at 3 and 18 months where just under a
third of participants did not attend. Uptake of the 3
months visit could have been influenced by either the
14-weeks immunization uptake and/or that it was the
Table 2 Baseline factors associated with ‘MV frequency’
Determinant Exposed at Baseline (N) MV frequency≥ 1 n (weighted %) Adjusted IRR 95% CI p-value
ALL -> 2650 1548 (58.8)
Caregiver
Mother 2607 1514 (58.4) ref
Other 43 34 (75.2) 0.8 0.6–1.2 0.251
Mother’s agea 0.01
13–24 years 681 447 (66.1) ref
25–34 years 1480 848 (56.8) 0.9 0.8–1.0 0.01
35–50 years 482 248 (53.5) 0.8 0.7–1.0 0.012
Disclosure of mother’s HIV status 0.128
Yes 2087 1144 (54.5) ref
No 455 305 (66.7) 1.1 1.0–1.3 0.057
Unknown 108 99 (89.6) 0.8 0.4–1.7 0.596
Mother on ART by 6 weeks 0.0003
Yes 1445 769 (53.1) ref
No 1083 668 (61.1) 1.2 1.1–1.4 < 0.0001
Unknown 122 111 (89.2) 1.8 0.9–3.5 0.083
Infant on NVP by 6 weeks 0.025
Yes 2329 1331 (56.4) ref
No 114 68 (62.2) 1.2 1.0–1.4 0.118
Unknown 207 159 (77.7) 1.4 1.1–1.8 0.02
Travel 0.012
Own car 99 70 (72.3) ref
Walked < 30 min 1182 674 (58.6) 0.7 0.6–0.9 0.002
Walked > 30 min 283 173 (59.1) 0.8 0.6–1.0 0.068
Public transport < 30min 872 498 (56.8) 0.7 0.6–0.9 0.004
Public transport > 30min 214 133 (61.5) 0.9 0.7–1.1 0.231
Province < 0.0001
WC 246 134 (56.7) ref
NW 221 112 (51.1) 1.2 0.9–1.5 0.305
NC 84 38 (46.3) 0.6 0.4–0.9 0.006
MP 315 193 (62.3) 1.3 1.0–1.7 0.025
LP 266 199 (73.8) 1.9 1.4–2.4 < 0.0001
KZN 442 226 (51.8) 1.3 1.0–1.6 0.103
GP 524 327 (63.7) 1.7 1.3–2.2 < 0.0001
FS 275 171 (62.4) 1.6 1.3–2.1 < 0.0001
EC 277 148 (55.1) 1.2 0.9–1.6 0.333
MV- missed visits at exposed postnatal care visits. IRR- incidence rate ratio. Significant p-values for the incidence rate ratio are in bold face
avariable has missing data of< 5%. All proportions were adjusted for survey sampling weights (W %). South African provinces- WC-Western Cape, NW-North West,
NC-Northen Cape, MP-Mpumalanga, LP-Limpopo, KZN-KwaZulu Natal, GP-Gauteng, FS-Free State, EC-Eastern Cape
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Table 3 Baseline factors associated with ‘MV at 18 months’
Determinant N MV at 18 month time point: n (weighted %) adjusted OR 95% CI p-value
All 2555 767 (31.0)
Mother’s age
13–24 years 655 240 (37.9) 1.0 Ref
25–34 years 1431 403 (28.6) 0.7 0.5–0.9 0.001
35–50 years 462 122 (28.0) 0.7 0.5–0.9 0.011
Education
Grade 7- 501 167 (34.2) 1.0 Ref
Grade 8+ 2050 599 (30.3) 0.8 0.6–1.1 0.174
Ever Breastfed
Yes 1811 558 (32.0) 1.0 Ref
No 680 188 (28.2) 0.9 0.7–1.2 0.623
Disclosure of HIV mother’s status
Yes 2009 578 (29.6) 1.0 Ref
No 444 154 (35.6) 1.2 0.9–1.5 0.247
Unknown 102 35 (35.7) 0.7 0.1–3.2 0.601
Discriminated against
No 2241 677 (85.5) 1.0 Ref
Yes 212 55 (8.6) 0.7 0.4–1.1 0.093
Unknown 102 35 (6.0) 1.2 0.8–2.0 0.398
Knows MTCT modes
Yes 2239 663 (30.5) 1.0 Ref
No 86 24 (32.1) 1.1 0.6–1.9 0.762
Unknown 230 80 (36.3) 1.2 0.8–1.8 0.381
Mother on ART by 6 weeks
Yes 1394 362 (26.9) 1.0 ref
No 1045 364 (35.4) 1.3 1.1–1.6 0.006
Unknown 116 41 (36.3) 1.9 0.4–8.0 0.396
Infant on NVP by 6 weeks
Yes 2251 664 (30.1) 1.0 ref
No 105 36 (40.3) 1.5 0.9–2.5 0.091
Unknown 199 67 (34.7) 1.2 0.7–2.2 0.437
SES
Highest 540 151 (28.6) 1.0 ref
High 448 111 (28.8) 1.0 0.7–1.5 0.906
Middle 522 155 (28.9) 1.0 0.7–1.3 0.857
Low 523 174 (33.8) 1.1 0.8–1.6 0.415
Lowest 522 176 (34.4) 1.1 0.8–1.6 0.512
Province
WC 239 32 (13.5) 1.0 Ref
NW 213 68 (32.3) 2.8 1.6–4.8 < 0.0001
NC 82 6 (7.2) 0.4 0.1–1.4 0.175
MP 299 93 (32.0) 2.7 1.5–4.6 0.001
LP 252 97 (37.0) 3.5 2.0–6.0 < 0.0001
KZN 433 144 (33.3) 3.0 1.8–5.0 < 0.0001
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first follow-up after enrolment [13]. Better uptake of
the 18 months visit was probably linked to the fact
that this is a major PMTCT end point visit and an
immunization time point. Furthermore, study incon-
venience allowances increased from USD$2.50 to
USD$6.00 to cover participant travel and time costs,
at eight calendar months before the study closure.
The change in allowance amount could have moti-
vated for better attendance thereafter at which most
upcoming visits were for the 15 and 18-month points.
It is also likely that maternal uptake of infant postna-
tal care is better when postnatal visits are fixed to
specific activities such as vaccination rather than
being labelled as a ‘general baby check-up’. It is also
important to note that the rate of non-attendance
could be lower under routine settings because partici-
pants were given inconvenience allowances during
these study visits, which could have motivated some
to return for follow-up.
The low uptake of study visits after 3 months is con-
sistent with what has been observed in routine settings
of other African countries. A study by Godfrey et al.
(2015) for example, found extremely low retention rates
for both mothers and infants between 4 and 12months
postpartum in Kenya, Malawi and Swaziland [14]. Sub-
optimal retention in care has also been a challenge
across different PMTCT regimen eras indicating that
improving the regimen alone is not a solution but new
and innovative strategies to promote better uptake of
HIV care are also needed [15–18].
Not receiving maternal ART by 6 weeks postpartum
was significantly associated with non-attendance regard-
less of how it was defined. Most importantly it was asso-
ciated with missing the 18-month visit, which is a
critical PMTCT visit as, in most countries, the 18-month
HIV test is used to measure the final outcome of
PMTCT interventions. Data collection for this study
began when Option A regimen was in use during preg-
nancy and ended when the local policy had moved to
Option B. For both Option A and Option B; ART was
initiated in pregnant women with a CD4 count of 350
and less. The results seen here could reflect the differ-
ences in women’s attitudes then, between women whose
lives were deemed to be at risk and hence on ART and
the rest who otherwise probably did not find it necessary
to attend as many visits. Unknown infant nevirapine-in-
take status at 6 weeks was associated with poor uptake
of postnatal visits. This could reflect general neglect of
child health issues and requires continued education and
encouragement of caregivers during routine child health
care visits. When looking at the breakdown of propor-
tions of MV per time-point (see Additional file 1), the
group with unknown infant nevirapine-intake had much
higher MV until the 9 months time-point, and this dif-
ference was significant. From 12months onwards, there
were no longer significant differences in MV proportions
between those who were on infant prophylaxis at 6
weeks, those who were not on infant prophylaxis at 6
weeks, and those who did not know the prophylaxis in-
take history. This finding, could mirror a change from
the use of Option A regimen (cessation of infant
prophylaxis at 6 weeks post cessation of breastfeeding)
to Option B (infant prophylaxis for 6 weeks postpartum).
That is, while Option A was active, infant prophylaxis
continued during breastfeeding and therefore promoted
infant visits to healthcare, to collect infant nevirapine,
until breastfeeding cessation. Yet after Option B was
implemented, infants were not required to be on nevira-
pine prophylaxis beyond 6 weeks postpartum, and thus
not required to attend health facilities for HIV-care and
prophylaxis. The influence of nevirapine intake on post-
natal visits was therefore lost with Option B regimen.
The significant results from the regression analyses
therefore show that the strength of association between
infant nevirapine prophylaxis intake and MV rates dur-
ing the era of Option A was very strong.
Mothers older than 24 years, compared to adolescent
and younger mothers were significantly associated with
fewer MV in both definitions of MV. This finding is not
surprising, given that provision of appropriate care for ad-
olescents and young mothers have been identified as a
critical gap in many countries [19–23]. Some earlier stud-
ies have consistently shown better awareness and uptake
of HIV care among older women across different coun-
tries [23–25], and thus appropriate interventions for the
younger age group are needed urgently. Interventions
focussing on creating friendly attitudes and safe environ-
ments for adolescent-mothers in public healthcare
facilities, aiming at making them feel as comfortable as
older women in healthcare facilities, are needed urgently.
Table 3 Baseline factors associated with ‘MV at 18 months’ (Continued)
Determinant N MV at 18 month time point: n (weighted %) adjusted OR 95% CI p-value
GP 510 151 (31.5) 3.1 1.8–5.4 < 0.0001
FS 265 106 (39.6) 4.1 2.4–7.2 < 0.0001
EC 262 70 (26.4) 2.1 1.2–3.8 0.014
MV- non-attendance at scheduled postnatal care visits. Significant p-values for the odds ratio are in bold face. All proportions were adjusted for survey sampling
weights (W %). South African provinces- WC-Western Cape, NW-North West, NC-Northen Cape, MP-Mpumalanga, LP-Limpopo, KZN-KwaZulu Natal, GP-Gauteng,
FS-Free State, EC-Eastern Cape
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It was interesting to find that participants who took
less time traveling to healthcare facilities, within 30min,
by walking or using public transport, had better out-
comes compared to those who owned cars. The latter
were not different from public transport users or walkers
who took longer than 30 min to reach the facilities.
Although it is not clear why those who owned cars per-
formed poorer than the second group, the findings show
that shorter time spent travelling to healthcare facilities
by walking or public transport is an important factor for
achieving good retention in care among mothers and
their young children. This finding of better uptake
among those with quicker access to facilities is not
unique to South Africa. Accessibility to health facilities,
in particular, availability of transport, transport costs
and longer distances is a known obstacle to uptake and
retention in care in other African settings [26, 27].
Investing in sustainable mobile clinics for the remote
settings could facilitate uptake of health care among
communities living far from healthcare facilities.
Significant differences between provinces were also
observed for both types of MV, raising the need to in-
vestigate province-specific barriers.
We did not find any association between missing post-
natal study visits and knowledge of MTCT modes or dis-
crimination and disclosure of maternal HIV status in
contrast to what has been reported by other earlier
studies [28]. The findings related to disclosure and
discrimination, in particular, are probably because dis-
closure was largely towards trusted close family or
friends only, thus did not affect uptake of health-related
care in any way. Also, a majority of the participants
(three-quarters of the sample) had disclosed their HIV
status and only less than 10% of participants reported fa-
cing discrimination indicating general improvements in
societal attitudes towards HIV and the stigmas which
were associated with it in the past. There was also no
clear association of MV rate with the type of caregiver at
baseline or socio-economic status. Lack of association
with the type of caregiver could simply be because 97%
of the participants were infant mothers.
Limitations
We measured non-attendance at scheduled study visits,
with a particular focus on the 18-month time point, and
used these study visits as a proxy for attendance at rou-
tine postnatal visits. However, we do not have data to
confirm that scheduled study visits coincided with rou-
tine postnatal visits. Given that we offered infant HIV
testing at each time point, and thus earlier referral into
care, we believe that this limitation was diluted by the
offer of earlier infant HIV diagnoses, as each visit could
be a proxy for attendance or uptake of earlier infant HIV
testing, a critical component of preventative child health
programmes in high HIV prevalence settings. The lack
of routine tracking systems did not allow us to establish
whether a child who missed their study visit attended a
different health facility for their routine child health visit.
Our findings raise the importance of patient tracking
systems, across rural and urban settings to ensure that
no mother-baby pair is lost from care.
The PMTCT regimen changed from Option A to
Option B guidelines mid-way of the cohort study, in
April 2013, which was the last month of baseline (6-
weeks post-partum) enrolment of participants. Although
we investigate association of MV with only baseline (in-
cluding antenatal experiences) characteristics, which
were all under the same regimen (Option A), follow-up
to study end-points over-lapped with Option B guide-
lines. The data collection process did not include indi-
vidual-level information on the specific time that they
were moved from Option A to Option B. For this rea-
son, it was not possible to accurately disentangle, nor
adjust in the regression models, the effects of treatment
policy change on MV, if any.
Recent South African studies, following the introduc-
tion (in 2015) of birth PCR HIV testing in infants, have
demonstrated poorer infant follow-up postnatally among
infants tested at birth [29, 30]. Therefore the retention
seen in this study may be an over-estimate of true
current retention.
Conclusions
In this nationally-representative sample, we studied non-
attendance at scheduled study visits where we offered
additional HIV testing (at 3, 6, 9, 12 and 15months
postpartum) and routine HIV testing at the final
PMTCT endpoint of 18-months. Despite us offering
these services, which facilitate earlier access to care, we
demonstrate that > 50% HEU did not attend one or
more scheduled study visits. Poor accessibility of clinics,
young age, poor maternal uptake of ART at 6 weeks
postpartum and child healthcare unawareness were risk
factors for non-attendance at the scheduled study visits
during the era of PMTCT Option A and B PMTCT regi-
mens. On-going exploration is needed to understand
and remove the barriers for postnatal care uptake in the
current era of lifelong ART. Strengthening community-
based health care linkages with the facilities could be
considered to facilitate tracing and ease of access if simi-
lar challenges persist.
Additional files
Additional file 1: Baseline characteristics at 6 weeks postpartum
presented by patterns of MV per time-point. MV- non-attendance at
scheduled postnatal care visits. Proportions of participants who missed
each follow-up visit point when they were eligible to attend it. The
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proportions are presented per sub-group of each baseline characteristic
measured at 6 weeks postpatrum, i.e., row percentages are given. Significant
chi-squared ps for differences in proportions of MV between sub-groups of
each baseline characteristic, per visit point, are presented in bold face. All
proportions were adjusted for survey sampling weights (W %). South
African provinces- WC-Western Cape, NW-North West, NC-Northen
Cape, MP-Mpumalanga, LP-Limpopo, KZN-KwaZulu Natal, GP-Gauteng,
FS-Free State, EC-Eastern Cape. (XLSX 17 kb)
Additional file 2: Actual number of missed visits (MV-frequency)
presented according to the number of scheduled (exposed) visits. The
number and percentage of participants who missed a specific number of
visits out of the total number of scheduled visits they were expected to
attend (exposed visits). The description of ‘exposed visits’ is given in
Methods under ‘Describing patterns of ‘missed visits” sub-heading. For
example, a total of 23 participants were expected to have attended
only 3 visits (3 was their total number of exposed visits), 7 of these
attended all the three visits (MV-frequency = 0) and 16 missed 1 visit.
(PDF 53 kb)
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